Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx has reported positive pre-clinical data that demonstrated the effectiveness of BL-2030, a soluble CCR2 receptor for the treatment of prostate cancer, in significantly reducing tumor growth and preventing metastasis to the lungs and bones of treated mice.
Subscribe to our email newsletter
The company believes that the tumor growth inhibition observed in pre-clinical studies is due to a specific binding of BL-2030 to CCL2. By inhibiting CCL2’s activity, BL-2030 impairs the recruitment of cells and factors that promote tumor development, resulting in inhibition of tumor progression and metastasis.
Due to this highly targeted mechanism, BL-2030 is expected to inhibit tumor growth with lower side effects than currently available treatments. In addition, the company believes that BL-2030 could complement existing hormonal and cytotoxic therapies currently employed for advanced prostate cancer.
BL-2030 was in-licensed from BioRap Technologies, a private company established to manage the commercialization of intellectual property developed by members of the Rappaport Family Institute for Research in the Medical Sciences at the Technion, Israel.
Morris Laster, CEO of BioLineRx, said: “These data support our view that BL-2030 has the potential to be a valuable treatment for prostate cancer, as well as other CCL2 implicated cancers and autoimmune diseases. We look forward to the initiation of the clinical trial program for this compound in 2008.”